… and analysing the clinical data, we analysed the efficacy and safety of anlotinib combined
with immunotherapy in the treatment of third-line NSCLC, in order to guide future clinicians in …

… preclinical and clinical trials of anlotinib were summarized with a focus on safety evaluation
… In the present review, the preclinical data and clinical trials of anlotinib are summarized and, …

… treated outside randomized clinical trials, … clinical trials and to monitor post-marketing safety
and adverse events. Citation7 In this study, we analyzed the efficacy and safety of anlotinib …

… Several preclinical and clinical trials have confirmed the … Furthermore, oral anlotinib
therapy during the coronavirus … Therefore, we investigated the efficacy and safety of anlotinib …

… In conclusion, we elucidated the efficacy and safety of anlotinib in a real-world setting. Anlotinib
is effective in the treatment of advanced NSCLC, which can bring longer survival benefits …

… and safety of anlotinib … the clinical benefit of anlotinib as third-line or more-line treatment
in patients with advanced lung cancer in the real world. The results demonstrated that anlotinib …

… used to study the efficacy and safety of anlotinib. As no standard third-line … NSCLC, anlotinib
has mainly been investigated in this … II clinical trial was conducted to estimate the safety and …

… treated with anlotinib plus … investigate the efficacy of anlotinib used alone and in combination
with other agents in advanced NSCLC, with special attention to the combination of anlotinib …

… The aim of this study was to investigate the efficacy and safety of anlotinib for patients with
advanced non-small cell lung cancer (NSCLC) who progressed after standard regimens in …

… The toxicity profile was generally consistent with the prior experience of anlotinib in phase
I study and the safety data of other multi-kinase inhibitors belonging to the same class (31). …